Here are relevant reports on : vocal-biomarkers-market
-
Cancer Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
The global cancer profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. The growth in this market is driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players. On the other hand, a low biomarker discovery-to-approval ratio and a poor regulatory and reimbursement scenario challenge the growth of the cancer profiling market.
- Published: November 2022
- Price: $ 4950
- TOC Available:
-
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), End-user, and Region - Global Forecast to 2029
The global cancer biomarkers market, valued at US$22.3 billion in 2023, stood at US$24.5 billion in 2024 and is projected to advance at a resilient CAGR of 11.3% from 2024 to 2029, culminating in a forecasted valuation of US$42.0 billion by the end of the period. The primary drivers of growth in this market are the rising incidence of cancer worldwide, increased research on cancer biomarkers, the growing use of biomarkers in drug discovery and development, and ongoing technical advancements.
- Published: April 2024
- Price: $ 7150
- TOC Available:
-
Europe Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Europe biomarkers Market, valued at US$16.40 billion in 2024, stood at US$17.46 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$28.11 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) & Geography
The global breast cancer liquid biopsy market is projected to grow at a CAGR of 23.1%. Factors such as increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the breast cancer liquid biopsy market. The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030
The global exosome research market, valued at US$189.4 million in 2024, stood at US$214.4 million in 2025 and is projected to advance at a resilient CAGR of 17.5% from 2025 to 2030, culminating in a forecasted valuation of US$480.6 million by the end of the period. The growth of the Asia Pacific exosome research market is primarily due to the growing biomedical industry, increasing life science research, and rising investments by pharmaceutical & biotechnology companies in this region.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030
The North America biomarkers Market, valued at US$23.35 billion in 2024, stood at US$25.13 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$45.25 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030
The global biomarkers market, valued at US$58.07 billion in 2024, stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
